Uterine Serous Carcinoma Market

Immunotherapy is estimated at 38.0% of treatment modality demand in 2026 with first-line therapy at 52.0% and hospital pharmacies at 48.0%. Adoption requires molecular testing and specialist infusion capacity despite small disease-specific populations that constrain evidence development.